Analyst Price Targets — BTAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2024 7:04 am | Graig Suvannavejh | Mizuho Securities | $1.00 | $0.59 | StreetInsider | Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI) |
| April 15, 2024 6:44 am | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $2.90 | StreetInsider | BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright |
| August 15, 2023 2:02 pm | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.98 | Benzinga | Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy |
| January 3, 2023 6:12 am | — | H.C. Wainwright | $73.00 | $21.48 | Benzinga | HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73 |
| November 11, 2022 8:50 am | — | Guggenheim | $25.00 | $14.82 | Benzinga | Guggenheim Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $25 |
Latest News for BTAI
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar…
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1.5 per share a year ago.
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc.…
BioXcel Therapeutics (BTAI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BTAI.
U.S. House Trading
No House trades found for BTAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.